The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
Based on the AFT Pharmaceuticals Ltd stock forecast from 0 analysts, the average analyst target price for AFT Pharmaceuticals Ltd is not available over the next 12 months. AFT Pharmaceuticals Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of AFT Pharmaceuticals Ltd is Slightly Bullish , which is based on 8 positive signals and 6 negative signals. At the last closing, AFT Pharmaceuticals Ltd’s stock price was AUD 3.07. AFT Pharmaceuticals Ltd’s stock price has changed by +6.97% over the past week, +6.23% over the past month and -9.17% over the last year.
No recent analyst target price found for AFT Pharmaceuticals Ltd
No recent average analyst rating found for AFT Pharmaceuticals Ltd
Company Overview AFT Pharmaceuticals Ltd
AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, gastrointestinal, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, vitamins, and supplements, as well as other products. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand. Address: 129 Hurstmere Road, Auckland, New Zealand, 0622 Read Less
AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, gastrointestinal, cold and flu, digestive health, ...Read More
Frequently Asked Questions About AFT Pharmaceuticals Ltd (AFP:AU) Stock
Stock Target Advisor's fundamental analysis for AFT Pharmaceuticals Ltd's stock is Slightly Bullish .
AFP:AU stock's dividend yield is 0.32%.
Our analysis grades AFP:AU stock's dividend yield at F. This means that AFP:AU stock's dividend yield is above 33% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the AU exchange.
Based on this AFP:AU may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on AFP:AU's stock to indicate what its average analyst target is.
AFP:AU stock's Price/Earning ratio is 21.93.
Our analysis grades AFP:AU stock's Price / Earning ratio at F. This means that AFP:AU stock's Price/Earning ratio is above 67% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the AU exchange.
Based on this AFP:AU may be a overvalued for its sector.
The last closing price of AFP:AU's stock was AUD 3.07.
The most recent market capitalization for AFP:AU is AUD 0.32B.
Unfortunately we do not have enough analyst data on AFP:AU's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains AFT Pharmaceuticals Ltd's stock.
As per our most recent records AFT Pharmaceuticals Ltd has 110 Employees.
AFT Pharmaceuticals Ltd's registered address is AmericaFirst Quantitative Funds.
You can get more information about it from AFT Pharmaceuticals Ltd's website at https://www.aftpharm.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About AFT Pharmaceuticals Ltd (AFP:AU) Stock
Stock Target Advisor's fundamental analysis for AFT Pharmaceuticals Ltd's stock is Slightly Bullish .
AFP:AU stock's dividend yield is 0.32%.
Our analysis grades AFP:AU stock's dividend yield at F. This means that AFP:AU stock's dividend yield is above 33% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the AU exchange.
Based on this AFP:AU may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on AFP:AU's stock to indicate what its average analyst target is.
AFP:AU stock's Price/Earning ratio is 21.93.
Our analysis grades AFP:AU stock's Price / Earning ratio at F. This means that AFP:AU stock's Price/Earning ratio is above 67% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the AU exchange.
Based on this AFP:AU may be a overvalued for its sector.
The last closing price of AFP:AU's stock was AUD 3.07.
The most recent market capitalization for AFP:AU is AUD 0.32B.
Unfortunately we do not have enough analyst data on AFP:AU's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains AFT Pharmaceuticals Ltd's stock.
As per our most recent records AFT Pharmaceuticals Ltd has 110 Employees.
AFT Pharmaceuticals Ltd's registered address is AmericaFirst Quantitative Funds.
You can get more information about it from AFT Pharmaceuticals Ltd's website at https://www.aftpharm.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AFP:AU !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
